A bi-polar hormone that can contribute to strokes and minimize their damage is emerging as a therapeutic target in the battle against these brain attacks, researchers say. Despite better management of ...
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), ...
High blood pressure is one of the most common health problems in the world. It affects more than 1.5 billion people and is a ...
Once-daily treatment with the selective aldosterone synthase inhibitor lorundrostat (Mineralys Therapeutics) safely and significantly reduced blood pressure in adults with uncontrolled hypertension in ...
A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high, despite taking several existing medicines, according to the results of a Phase III ...
Welltica+ on MSN
Researchers test new drug for high blood pressure – and it works
Discover the promising results of a new drug, baxdrostat, tested for high blood pressure in patients with chronic kidney disease. This video explores how the medication targets the hormone aldosterone ...
A bi-polar hormone that can contribute to strokes and minimize their damage is emerging as a therapeutic target in the battle against these brain attacks, researchers say. "It costs about $56 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results